Ready for Smooth Season
Starting weight loss therapy with uncontrolled hypothyroidism may: Confound assessment of treatment efficacy Complicate symptom attribution (fatigue, constipation overlap) Necessitate multiple medication adjustments simultaneously Practically speaking, patients may benefit from demonstrating stable thyroid function on consistent levothyroxine dosing before adding weight loss medications, though this is not a strict requirement
The mean baseline body weight was 93.2 kg, 95.5 kg and 92.9 kg in the placebo, liraglutide 1.8 mg and RYBELSUS 14 mg arms, respectively
Before you buy a single vial, understand what you are working with
Key findings from OASIS 4: Patients taking the oral semaglutide 25 mg pill lost an average of 13.6% of body weight versus 2.4% for placebo, when looking at all participants regardless of whether they stayed on treatment Among patients who completed the full course, average weight loss reached 16.6% , compared to 2.7% with placebo More than one-third of adherent participants lost 20% or more of their body weight 76% of patients on the pill lost at least 5% of body weight, versus 31% on placebo Participants also showed improvements in blood pressure, waist circumference, LDL cholesterol, and triglycerides Serious adverse events were actually less frequent with oral semaglutide than placebo (3.9% vs
